The history of Crohn’s disease stretches back far beyond its formal medical classification in the 1930s, weaving a complex narrative through ancient medical texts, ambiguous case studies, and the evolving understanding of inflammatory bowel disease. Day to day, while the condition bears the name of Dr. So burrill Bernard Crohn, who alongside colleagues Leon Ginzburg and Gordon D. Plus, oppenheimer published the landmark paper Regional Ileitis in 1932, the pathology itself has likely afflicted humanity for centuries. Understanding how long Crohn’s has been around requires distinguishing between the clinical entity as we define it today and the symptomatology described by physicians throughout history.
The Landmark 1932 Discovery
To understand the modern timeline, one must start with the central moment at Mount Sinai Hospital in New York. Day to day, before 1932, chronic inflammation of the terminal ileum was frequently misdiagnosed as intestinal tuberculosis, a rampant disease at the time. Surgeons often resected the affected bowel, assuming the mass was malignant or tuberculous Easy to understand, harder to ignore..
Dr. Crohn and his team meticulously analyzed 14 surgical specimens and clinical records. But they identified a distinct pathological pattern: transmural inflammation (affecting all layers of the bowel wall), skip lesions (healthy tissue interspersed between diseased segments), non-caseating granulomas, and a predilection for the terminal ileum. Their publication in the Journal of the American Medical Association (JAMA) effectively separated "regional ileitis" from tuberculosis and cancer Easy to understand, harder to ignore..
This moment marks the "official" birth of Crohn’s disease in medical nomenclature. On the flip side, the paper itself acknowledged prior descriptions. The question remains: were those earlier descriptions the same disease?
Pre-1932: The "Hidden" History
Long before Mount Sinai, physicians documented cases that bear a striking resemblance to modern Crohn’s disease. The challenge lies in retrospective diagnosis; without histopathology, endoscopy, or imaging, doctors relied on gross anatomy at autopsy or laparotomy And that's really what it comes down to..
Giovanni Battista Morgagni (1682–1771) Often called the father of modern anatomical pathology, Morgagni published De Sedibus et Causis Morborum (The Seats and Causes of Diseases) in 1761. In it, he described a young man suffering from chronic diarrhea, fever, and wasting. At autopsy, Morgagni found an ulcerated, thickened terminal ileum with enlarged mesenteric lymph nodes. While he attributed it to "phthisis" (a term often used for tuberculosis), the description of isolated terminal ileal disease aligns closely with Crohn’s Small thing, real impact. Less friction, more output..
John Abercrombie (1780–1844) In 1828, the Scottish pathologist described "chronic inflammation of the ileum and colon" in his Pathological and Practical Researches on Diseases of the Intestines. He noted ulceration and thickening distinct from dysentery or simple inflammation, though he, too, struggled to differentiate it from TB.
The Polish Contribution: Antoni Leśniowski (1867–1940) A critical, often overlooked milestone occurred in 1904. Leśniowski, a Polish surgeon, published a paper describing "chronic inflammation of the intestine" with features—skip lesions, transmural fibrosis, and fistula formation—that are pathognomonic for Crohn’s. He presented surgical specimens showing the disease affecting the small bowel, colon, and even the esophagus. In many parts of Europe, particularly Poland and Germany, the condition is still referred to as Leśniowski-Crohn disease, acknowledging his priority in the full clinical-pathological description Took long enough..
Kennedy Dalziel (1871–1938) In 1913, the Scottish surgeon Dalziel presented 13 cases of "chronic interstitial enteritis" to the British Medical Association. He argued forcefully that this was a distinct entity separate from tuberculosis, noting the absence of the tubercle bacillus in tissues. His work was largely ignored by the broader medical community at the time, overshadowed by the prevailing dogma that chronic granulomatous bowel disease was tuberculosis.
The Tuberculosis Confusion: A Major Historical Obstacle
The reason Crohn’s disease remained "hidden" for so long was the dominance of tuberculosis (TB). In the late 19th and early 20th centuries, TB was the leading cause of death in the Western World. Robert Koch’s discovery of Mycobacterium tuberculosis in 1882 cemented the bacteriological model of disease.
Because Crohn’s disease produces granulomas (clusters of immune cells) that look remarkably similar to TB granulomas under a microscope—and because both cause weight loss, fever, abdominal pain, and strictures—physicians assumed they were the same. The "acid-fast bacillus" stain became the arbiter of truth. If the stain was negative, doctors often assumed the bacillus was simply hiding or dead, rather than accepting a non-infectious etiology.
It wasn't until the 1932 paper, combined with improved staining techniques and the failure of anti-tubercular treatments on these patients, that the medical establishment began to accept a non-infectious, idiopathic inflammatory condition Small thing, real impact..
The Evolution of Nomenclature and Understanding
Following the 1932 publication, the timeline of Crohn’s disease accelerates rapidly, defined by shifts in terminology, pathophysiology, and treatment.
1930s–1950s: Regional Enteritis and Surgical Management For two decades, the condition was widely known as regional enteritis or regional ileitis. The primary treatment was surgical resection. The prevailing philosophy was "cut out the bad segment." That said, high recurrence rates at anastomosis sites (surgical connections) soon proved the disease was systemic, not localized Practical, not theoretical..
1950s–1960s: The Granuloma Confirmation and Colon Involvement In the 1950s, pathologists like Morson and Dawson in the UK confirmed the presence of non-caseating granulomas as a histological hallmark, solidifying the distinction from ulcerative colitis (which lacks granulomas). Simultaneously, surgeons recognized the disease could affect the colon (Crohn’s colitis) and the entire GI tract, leading to the term Crohn’s disease replacing regional enteritis Worth keeping that in mind..
1970s–1980s: The Immunological Shift The discovery that corticosteroids (prednisone) could induce remission in the 1950s was the first hint that the immune system drove the pathology. By the 1970s and 80s, research pivoted definitively toward immune dysregulation. The identification of T-cell involvement, cytokine cascades (specifically TNF-alpha), and genetic susceptibility (the NOD2/CARD15 gene discovery in 2001) transformed Crohn’s from a surgical curiosity into a complex immunogenetic disorder.
1990s–Present: The Biologic Era The approval of infliximab (Remicade) in 1998 marked the dawn of targeted therapy. Anti-TNF agents changed the natural history of the disease, shifting goals from symptom control to mucosal healing and deep remission. Today, the treatment arsenal includes anti-integrins (vedolizumab), anti-IL-12/23 (ustekinumab), JAK inhibitors (upadacitinib), and biosimilars, reflecting a sophisticated understanding of the inflammatory pathways first hinted at in those 1932 surgical specimens And it works..
Ancient Echoes: Paleopathology and Historical Figures
Can we trace Crohn’s further back than the 1700s? Paleopathology—the study of disease in ancient remains—offers tantalizing clues but few definitive answers.
- Mummies and Skeletons: Researchers have
